


-116-

We claim:

1. A compound of formula



wherein

n is 0, 1, 2, or 3;

q is 0, 1, or 2;

W, X, Y and Z are each independently CH, C, N, S, or O with appropriate single or double bonds and/or hydrogen atoms to complete valency requirements;

Ring A is a five or six member ring wherein one of W, X, Y and Z may be absent; provided that ring A is not phenyl;

K is a bond, C=O, or S(O)_p;

p is 0, 1 or 2;

R¹ when n is 0, and k is C=O or S(O)_p, is selected from a group consisting of -OC₁-C₆ alkyl, -O-aryl, -OC₂-C₆ alkenyl, -OC₁-C₆ haloalkyl, -OC₁-C₆ alkylheterocyclic, -OC₃-C₈ cycloalkyl, -OC₁-C₆ alkylcycloalkyl, -NR⁷R⁸, -OC₁-C₆ alkylaryl, -OC₁-C₆alkylCO₂R¹¹, -OC₂-C₆alkylalcohol, -OC₁-C₆ alkylNR⁷R⁸, -OC₂-C₆ alkylcyano, CONR¹¹R¹², NR¹¹SO₂R¹², NR¹¹COR¹², C₂-C₃ alkylNR¹¹R¹², C₁-C₃ alkylCOR¹¹, C₀-C₆ alkylCOOR¹¹ and wherein each cycloalkyl, aryl and heterocyclic group is optionally substituted with 1 to 3 groups independently selected from oxo, hydroxy, halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, -C₁-C₆ alkylalcohol, OC₂-C₆ alkylalcohol, C₁-C₆ haloalkoxy, CONR¹¹R¹², NR¹¹SO₂R¹², NR¹¹COR¹², C₀-C₃ alkylNR¹¹R¹², C₁-C₃ alkylCOR¹¹, C₀-C₆ alkylCOOR¹¹, C₀-C₆ alkylcyano, -OC₂-C₆alkylcyano, C₁-C₆ alkylcycloalkyl, phenyl, -OC₁-C₆ alkylcycloalkyl, -OC₁-C₆ alkylaryl, -OC₁-C₆ alkylheterocyclic, and C₁-C₆ alkylaryl;

R¹ when n is 1 or 2 or 3, and K is a bond, is selected from a group consisting of hydroxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₆ haloalkyl, C₁-C₆ alkylheterocyclic, C₃-C₈ cycloalkyl,

C₁-C₆ alkylcycloalkyl; C₁-C₆ alkylaryl, aryl, heterocyclyl, C₁-C₆ alkylalcohol, C₁-C₆ alkylNR⁷R⁸, wherein each cycloalkyl, aryl and heterocyclic is optionally substituted with 1 or 2 groups independently selected from the groups consisting of oxo, hydroxy, halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, -C₁-C₆ alkylalcohol, OC₂-C₆ alkylalcohol, C₁-C₆ haloalkoxy, CONR¹¹R¹², NR¹¹SO₂R¹², NR¹¹COR¹², C₀-C₃ alkylNR¹¹R¹², C₁-C₃ alkylCOR¹¹, C₀-C₆ alkylCOOR¹¹, C₀-C₆ alkylcyano, -OC₂-C₆alkylcyano, C₁-C₆ alkylcycloalkyl, phenyl, -OC₁-C₆ alkylcycloalkyl, -OC₁-C₆ alkylaryl, -OC₁-C₆ alkylheterocyclic, and C₁-C₆ alkylaryl;

R² is each independently selected from the group consisting of hydrogen, halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, OC₁-C₆ alkyl, C₁-C₆ alkylaryl, aryl, C₀-C₆ alkylNR⁷R⁸, heteroaryl, heterocyclyl, C₃-C₈ cycloalkyl, C₁-C₆ alkylcycloalkyl and C₁-C₆ alkylheterocyclyl; wherein each cycloalkyl, aryl, or heterocyclic is optionally substituted with 1 to 3 groups independently selected from oxo, hydroxy, halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alcohol, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, CONR¹¹R¹², NR¹¹SO₂R¹², NR¹¹COR¹², C₀-C₃ alkylNR¹¹R¹², C₁-C₃ alkylCOR¹¹, C₀-C₆ alkylCOOR¹¹, cyano, and phenyl;

R³ is each independently selected from hydrogen, C₁-C₆ alkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkylaryl, C₁-C₆ alkylheterocyclic, C₃-C₈ cycloalkyl, or C₁-C₆ alkylcycloalkyl;

R⁴ is a group represented by the formula -NR⁹R¹⁰;

R⁵ is selected from the group consisting of hydrogen, halogen, hydroxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkylcycloalkyl, C₁-C₆ alkylaryl, C₁-C₆ alkylheterocyclic, aryl, C₁-C₆ alkylaryl, heteroaryl, aryloxy, -OC₂-C₆ alkenyl, -OC₁-C₆ haloalkyl, -NR⁷R⁸, and -OC₁-C₆ alkylaryl; and wherein when q is 1, 2 or 3, two adjacent R⁵ groups may combine to form a fused 5 or 6 member optionally substituted carbocyclic or heterocyclic ring with ring A;

R⁶ is independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, hydroxy, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkoxy, aryloxy, -OC₂-C₆ alkenyl, -OC₁-C₆ haloalkyl, C₁-C₆ alkylNR⁷R⁸, C₃-C₈ cycloalkyl, and C₁-C₆ alkylcycloalkyl;

R⁷ and R⁸ are independently selected from the group consisting of hydrogen, C₁-C₆ alkylcycloalkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkylheterocyclic, C₁-C₆ haloalkyl, NR¹¹R¹², hydroxy, oxo, COOH, C(O)OC₁-C₄ alkyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-

C₆ alkoxy, C₁-C₆ alkylalcohol, C₁-C₆ alkylamine, C₁-C₆ alkylaryl, C₂-C₆ alkenylaryl, C₂-C₆ alkynylaryl, C₁-C₆ alkyl-O-C₁-C₆ alkylaryl, C₁-C₆ alkyl-NR¹¹-C₁-C₆ alkylaryl, C₁-C₆ alkylcyano, C₁-C₆ alkylCONR⁷R⁸, C₁-C₆ alkylNR⁷R⁸, C₁-C₆alkylNR¹¹COR¹², and aryl, wherein each cycloalkyl or aryl group is optionally substituted with halo, hydroxy, oxo, amino, COOH, C(O)OC₁-C₄ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylalcohol, and C₁-C₆ alkylamine;

or R⁷ and R⁸ combine to form a nitrogen containing heterocyclic ring which may have 0, 1, or 2 additional hetero-atoms selected from oxygen, nitrogen or sulfur and may be optionally substituted with oxo, or C₁-C₆ alkyl;

R⁹ is the group C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₈ cycloalkyl, C₁-C₆ alkylcycloalkyl, aryl, heterocyclic, C₁-C₆ alkylheterocyclic, COR⁷, CO₂R⁷, C₀-C₃ alkylCONR⁷R⁸, C₀-C₃ alkylS(O)_pNR⁷R⁸, or C₀-C₃ alkylS(O)_pR⁷ wherein R⁷ is as defined above, and wherein each alkyl, cycloalkyl, aryl, and heterocyclic is optionally substituted with one to two groups independently selected from halo, hydroxy, oxo, COOH, C(O)OC₁-C₄ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylalcohol, C₁-C₆ alkylamine, C₁-C₆ alkylaryl, C₂-C₆ alkenylaryl, C₂-C₆ alkynylaryl, C₁-C₆ alkylheterocyclic, -NR⁷R⁸, C₃-C₈ cycloalkyl, C₁-C₆ alkylcycloalkyl, C₁-C₆ alkyl-O-C₁-C₆ alkylaryl, C₁-C₆ alkyl-NR¹¹-C₁-C₆ alkylaryl, C₁-C₆ alkylcyano, C₁-C₆ alkylCONR⁷R⁸, C₁-C₆ alkylNR⁷R⁸, C₁-C₆alkylNR¹¹COR¹², and aryl, wherein each cycloalkyl or aryl group is optionally substituted with halo, hydroxy, oxo, amino, COOH, C(O)OC₁-C₄ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylalcohol, and C₁-C₆ alkylamine;

R¹⁰ is selected from the group consisting of aryl, C₁-C₆ alkylaryl, C₂-C₆ alkenylaryl, C₂-C₆ alkynylaryl, C₁-C₆ haloalkylaryl, C₁-C₆ alkylheterocyclic, C₂-C₆ alkenylheterocyclic, C₁-C₆ alkylcycloalkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkyl-O-C₁-C₆ alkylaryl, and wherein each cycloalkyl, aryl, or heterocyclic group is optionally substituted with 1-3 groups independently selected from the group consisting of hydroxy, oxo, -SC₁-C₆ alkyl, C₁-C₆ alkyl, C₁-C₆ alkenyl, C₁-C₆ alkynyl, C₁-C₆ haloalkyl, halogen, C₁-C₆ alkoxy, aryloxy, C₁-C₆ alkenyloxy, C₁-C₆ haloalkoxyalkyl, C₀-C₆ alkylNR¹¹R¹², -OC₁-C₆ alkylaryl, nitro, cyano, -OC₁-C₆ haloalkyl, C₁-C₆ haloalkylalcohol, and C₁-C₆ alkylalcohol;

R¹¹ and R¹² are independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₁-C₆ alkenyl, C₃-C₈ cycloalkyl, heterocyclic, aryl, and C₁-C₆ alkylaryl, wherein

each aryl group is optionally substituted with 1-3 groups independently selected from halogen, C₁-C₆ alkylheterocyclic, and C₁-C₆ haloalkyl, or R¹¹ and R¹² combine to form a nitrogen containing heterocyclic ring which may have 0, 1, or 2 additional heteroatoms selected from oxygen, nitrogen or sulfur and is optionally substituted with oxo, or C₁-C₆ alkyl; or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture of diastereomers thereof.

2. A compound according to Claim 1 wherein n is zero, k is C=O and R¹ is selected from a group consisting of -OC₁-C₆ alkyl, O-aryl, -OC₂-C₆ alkenyl, -OC₁-C₆ haloalkyl, -OC₃-C₈ cycloalkyl, -OC₁-C₆ alkylcycloalkyl, -OC₁-C₆ alkylaryl, -O heterocyclic, and -OC₁-C₆alkylCO₂R¹¹, -OC₂-C₆alkylalcohol, -OC₁-C₆ alkylNR⁷R⁸, -OC₂-C₆ alkylcyano -OC₁-C₆ alkylheterocyclic, wherein each cycloalkyl, aryl and heterocyclic group is optionally substituted with 1 to 3 groups independently selected from C₀-C₆ alkylCOOR¹¹, C₀-C₆ alkylalcohol, C₀-C₃ alkylNR¹¹R¹², and C₀-C₆ alkylcyano.

3. A compound according to Claim 1 wherein n is 1, k is a bond and R¹ is selected from a group consisting of C₂-C₆ alkenyl, C₂-C₆ haloalkyl, C₃-C₈ cycloalkyl, aryl, and heterocyclic wherein each cycloalkyl, aryl, or heterocyclic is optionally substituted with 1 or 2 groups selected from C₁-C₃ alkylalcohol, C₁-C₃ alkylamine, C₀-C₃ alkylCOOH, C₀-C₃ alkylCONH₂, and C₀-C₃ alkylC(O)OC₁-C₃ alkyl.


4. A compound according to Claim 1 wherein R⁴ is NR⁹R¹⁰ and R⁹ is a heterocyclic group optionally substituted with one to two groups independently selected from OH, halo, amino, C(O)OC₁-C₄ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₁-C₆ alkylalcohol, C₁-C₆ alkylamine, C₃-C₈ cycloalkyl, and C₁-C₆ alkylcycloalkyl, C₁-C₆ alkylcyano, C₁-C₆alkylCONR⁷R⁸, C₁-C₆alkylCO₂R¹¹.

5. A compound according to Claim 1 wherein the A ring is selected from the group consisting of pyridine, pyrazine, thiophene, pyrazole isoxazole, oxazole, and thiazole.

6. A compound according to Claim 1 wherein the A ring is pyridine.

7. A compound according to Claim 1 wherein the A ring is thiophene.


8. A compound according to Claim 1 wherein each R^3 is hydrogen and R^4 is NR^9R^{10} and R^9 is selected from the group consisting of:



wherein R is independently H, OH, NR^7R^8 or C_1 - C_3 alkyl wherein C_1 - C_3 alkyl group is optionally substituted with OH, halo, cyano, $CONR^7R^8$, CO_2R^{11} , or NR^7R^8 .

9. A compound according to Claim 1 wherein two R^5 groups combine to form a fused cyclopentane or cyclohexane ring with ring A.

10. A compound according to Claim 1 wherein R^4 is selected from the group consisting of:



wherein R⁷ is OH, C₁-C₃ alkyl, -OC₁-C₃ alkyl, or C₁-C₃ haloalkyl.

11. A compound selected from the group consisting of:

4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-7-methyl-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid isopropyl ester,

Cis-4-[acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

Cis-4-[(3,5-bis-trifluoromethyl-benzyl)-(2H-tetrazol-5-yl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

Cis-4-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

7-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-5-ethyl-6,7-dihydro-5*H*-thieno[3,2-*b*]pyridine-4-carboxylic acid isopropyl ester,
(+/-)-cis-4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(+/-)-cis-4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-bromo-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(+/-)-cis-4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-dimethylamino-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(+/-)-cis-4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(+/-)-cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-2-methyl-2*H*-tetrazol-5-yl]-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*S*,4*R*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-2-methyl-2*H*-tetrazol-5-yl]-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-2-methyl-2*H*-tetrazol-5-yl]-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(+/-)-cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-[2-(2-*tert*-butoxycarbonylamino-ethyl)-2*H*-tetrazol-5-yl]-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester ,
(+/-)-cis-4-[[2-(2-Amino-ethyl)-2*H*-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*S*,4*R*)-cis-4-[[2-(2-Amino-ethyl)-2*H*-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)-cis-4-[[2-(2-Amino-ethyl)-2*H*-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(+/-)-cis and trans-4-[(3,5-Bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-2*H*-tetrazol-5-yl]-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(2*S*,4*R*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-4-[(3,5-Bis-trifluoromethyl-benzyl)-[2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-[2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester trifluoroacetate,

(2*S*,4*R*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-[2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester trifluoroacetate,

(+/-)-cis-4-[[2-(2-Amino-ethyl)-2*H*-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-6-Amino-4-[(3,5-bis-trifluoromethyl-benzyl)-[2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-7-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-trans-6-Amino-4-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-7-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-methoxy-7-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid ethyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 2-dimethylamino-ethyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid tetrahydro-pyran-4-yl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 1-methyl-piperidin-4-yl ester,

(2*R*,3'*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid tetrahydro-furan-3-yl ester,

(2*R*,3'*S*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid tetrahydro-furan-3-yl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 2-morpholin-4-yl-ethyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 2-(4-methyl-piperazin-1-yl)-ethyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 2-methoxycarbonyl-2-methyl-propyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 2-carboxy-2-methyl-propyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 2-cyano-ethyl ester,

(2*R*,4*S*)- 4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 2-(2*H*-tetrazol-5-yl)-ethyl ester,

(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 2-benzyloxyethyl ester,

(2*R*,4*S*)- 4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid 2-hydroxy-ethyl ester,

(+/-)-cis-4-[(3,5-Bistrifluoromethylbenzyl)-(5-methyl-1*H*-pyrazol-3-yl)amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-4-[(3,5-Bis-trifluoromethylbenzyl)-(3-methyl-isoxazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-(5-methyl-[1,2,4]oxadiazol-3-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2,5-dimethyl-2*H*-pyrazole-3-carbonyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester,

(+/-)-cis-4-(3,5-Bis-trifluoromethyl-benzyl)-1-(cyclopentylmethyl-2-ethyl-6-methoxy-1,2,3,4-tetrahydro-[1,5]naphthyridine-4-yl)-acetamide,

(+/-)-cis-4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-6-methoxy-2-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-ethoxycarbonyl-amino]-6-methoxy-2-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-(3-fluoro-5-trifluoromethyl-benzoyl)-amino]-6-methoxy-2-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-*N*-(3,5-Bis-trifluoromethyl-benzyl)-*N*-(1-cyclopentyl-6-methoxy-2-methyl-1,2,3,4-tetrahydro-[1,5]naphthyridin-4-yl)-acetamide,

(+/-)-cis-4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(+/-)-cis-4-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(+/-)-cis-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazole-5-yl)-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
4-[(3,5-Bis-trifluoromethyl-benzyl)-(5,6,7,8-tetrahydro-quinolin-3-yl)-amino]-2,3-dimethyl-3,4,6,7,8,9-hexahydro-2*H*-benzo[b][1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid methyl ester,
(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid ethyl ester,
(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2,6-dimethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid methyl ester,
(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2,6-dimethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid ethyl ester,
(2*R*,4*S*)-4-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2,6-dimethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)-4-[(3-Cyano-5-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)-4-[(3,5-Dichloro-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)-4-[(3-Chloro-5-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)-2-Ethyl-4-[(3-fluoro-5-trifluoromethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)-4-[(3,5-Dimethyl-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,

(2*R*,4*S*)-4-[(3,5-Difluoro-benzyl)-(2-methyl-2*H*-tetrazol-5-yl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)- 4-[[2-(2-Amino-ethyl)-2*H*-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid methyl ester,
(2*R*,4*S*)- 4-{(3,5-Bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-2*H*-tetrazol-5-yl]-amino}-2-ethyl-6-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid methyl ester,
(2*R*,4*S*)- 4-[[2-(2-Amino-ethyl)-2*H*-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid ethyl ester,
(2*R*,4*S*)- 4-{(3,5-Bis-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-2*H*-tetrazol-5-yl]-amino}-2-ethyl-6-methyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid ethyl ester,
(2*R*,4*S*)- 4-[[2-(2-Amino-ethyl)-2*H*-tetrazol-5-yl]-(3-cyano-5-trifluoromethyl-benzyl)-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester,
(2*R*,4*S*)- 4-{(3-Cyano-5-trifluoromethyl-benzyl)-[2-(2-hydroxy-ethyl)-2*H*-tetrazol-5-yl]-amino}-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-[1,5]naphthyridine-1-carboxylic acid isopropyl ester
or a pharmaceutically acceptable salt, solvate enantiomer or diastereomer or mixture thereof.

12. A method of regulating CETP activity comprising administering a compound of formula I, a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture of diastereomers to a patient in need thereof.

13. A method of treating or preventing dyslipidemia comprising administering a compound of formula I, a pharmaceutically acceptable salt, solvate, enantiomer, racemate diastereomer, mixture of diastereomers thereof, to a patient in need thereof.

14. A method of treating or preventing arteriosclerosis comprising administering a compound of formula I, a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof to a patient in need thereof.
15. A method according to Claim 12, wherein the regulation of CETP activity results in a decrease in LDL-cholesterol.
16. A method according to Claim 12, wherein the regulation of CETP activity results in an increase in LDL-cholesterol.
17. A method of increasing plasma HDL-cholesterol in a mammal comprising administering a therapeutically effective dose of a compound of formula I, a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof to a patient in need thereof.
18. A method of treating and/or preventing the pathological sequelae due to high levels of plasma LDL-cholesterol in a mammal comprising administering an effective dose of a compound of formula I, pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer, or mixture of diastereomers to a patient in need thereof.
19. A pharmaceutical composition comprising a compound according to Claim 1 and a carrier, diluent and/or excipient.
20. Use of a compound of formula I for the manufacture of a medicament for treating and/or preventing atherosclerosis in a mammal comprising administering an effective dose of a compound of formula I, a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof to a patient in need thereof.